Is Big Pharma tiptoeing into embryonic stem cells?
By David Hamilton,
Venture Beat
| 04. 17. 2007
For what appears to be the first time, a major drug company has plunked down a significant equity investment in embryonic stem cells.
Earlier today, VentureWire reported (sub required) that Novocell, an early-stage San Diego biotech that aims to treat diabetes with the embryonic cells, is hoping to raise $35 million in a third round of funding. The interesting thing, however, isn't so much the money as the identity of the lead investor: Johnson & Johnson Development Corp., the venture arm of pharmaceutical giant J&J.
The news grabbed my attention because to date, Big Pharma has shown relatively little interest in the smaller biotechs working on embryonic stem-cell therapeutics, with the standard explanation that the field is too young and in need of some solid clinical success before the big guys can get involved. Political controversy over the destruction of embryos - necessary to derive the stem cells - probably also inclines the naturally cautious pharmas to move even more carefully. (Novacell intends to make new insulin-producing islet cells from embryonic cells, then transplant them into diabetics.)
Here are some...
Related Articles
By Emma McDonald Kennedy
| 04.24.2025
A Review of Eggonomics: The Global Market in Human Eggs and the Donors Who Supply Them by Diane M. Tober
A recent journalistic investigation of the global egg trade at Bloomberg put the industry’s unregulated practices and their exploitative implications back in the spotlight. Diane Tober’s book Eggonomics: The Global Market in Human Eggs and the Donors Who Supply Them, published in October of last year, delves even more deeply into the industry with a thorough examination of egg...
By Nafeez Ahmed, Byline Times | 04.04.2025
It’s hard to believe, but it’s happening. On 27 March 2025, President Donald Trump issued an Executive Order, ‘Restoring Truth and Sanity to American History’. Among its main concerns was the Smithsonian American Art Museum which, the order complained...
Gray wolf by Jessica Eirich via Unsplash
“I’m not a scarcity guy, I’m an abundance guy”
– Colossal co-founder and CEO Ben Lamm, The New Yorker, 4/14/25
Even the most casual consumers of news will have seen the run of recent headlines featuring the company Colossal Biosciences. On March 4, they announced with great fanfare the world’s first-ever woolly mice, as a first step toward creating a woolly mammoth. Then they topped that on April 7 by unveiling one...
By Katrina Northrop, The Washington Post | 04.06.2025
photo via Wikimedia Commons licensed under CC by 3.0
China's most infamous scientist is attempting a comeback. He Jiankui, who went to jail for three years after claiming he had created the world's first genetically altered babies, says he remains...